Messenheimer JA. Lamotrigine Epilepsia. 1995;36:S87-94.

CAS  PubMed  Google Scholar 

Vinik A. CLINICAL REVIEW: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. 2005;90:4936–45.

Article  CAS  PubMed  Google Scholar 

Doig MV, Clare RA. Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug. Lamotrigine J Chromatogr. 1991;554:181–9.

Article  CAS  PubMed  Google Scholar 

Sinz MW, Remmel RP. Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metab Dispos. 1991;19:149–53.

CAS  PubMed  Google Scholar 

Tukey RH, Strassburg CP. Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease. Annu Rev Pharmacol Toxicol. 2000;40:581–616.

Article  CAS  PubMed  Google Scholar 

Court MH, Zhang X, Ding X, Yee KK, Hesse LM, Finel M. Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica. 2012;42:266–77.

Article  CAS  PubMed  Google Scholar 

Green MD, Tephly TR. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos. 1996;24:356–63.

CAS  PubMed  Google Scholar 

Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos. 2006;34:1055–62.

Article  CAS  PubMed  Google Scholar 

Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009;39:355–63.

Article  CAS  PubMed  Google Scholar 

Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers. Xenobiotica. 2021;51:1146–54.

Article  CAS  PubMed  Google Scholar 

Kaivosaari S, Finel M, Koskinen M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica. 2011;41:652–69.

Article  CAS  PubMed  Google Scholar 

Jin CJ, Miners JO, Lillywhite KJ, Mackenzie PI. cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun. 1993;194:496–503.

Article  CAS  PubMed  Google Scholar 

Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Res. 2007;67:9024–9.

Article  CAS  PubMed  Google Scholar 

Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, Finel M. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol. 2007;72:761–8.

Article  CAS  PubMed  Google Scholar 

Kazmi F, Barbara JE, Yerino P, Parkinson A. A Long-Standing Mystery Solved: The Formation of 3-Hydroxydesloratadine Is Catalyzed by CYP2C8 But Prior Glucuronidation of Desloratadine by UDP-Glucuronosyltransferase 2B10 Is an Obligatory Requirement. Drug Metab Dispos. 2015;43:523–33.

Article  CAS  PubMed  Google Scholar 

Kato Y, Izukawa T, Oda S, Fukami T, Finel M, Yokoi T, et al. Human UDP-Glucuronosyltransferase (UGT) 2B10 in Drug N-Glucuronidation: Substrate Screening and Comparison with UGT1A3 and UGT1A4. Drug Metab Dispos. 2013;41:1389–97.

Article  CAS  PubMed  Google Scholar 

Fowler S, Kletzl H, Finel M, Manevski N, Schmid P, Tuerck D, et al. A UGT2B10 Splicing Polymorphism Common in African Populations May Greatly Increase Drug Exposure. J Pharmacol Exp Ther. 2015;352:358–67.

Article  PubMed  Google Scholar 

Chen G, Dellinger RW, Sun D, Spratt TE, Lazarus P. Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10. Drug Metab Dispos. 2008;36:824–30.

Article  CAS  PubMed  Google Scholar 

Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO. Influence of N-Terminal Domain Histidine and Proline Residues on the Substrate Selectivities of Human UDP-Glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos. 2009;37:1948–55.

Article  CAS  PubMed  Google Scholar 

Di L, Umland JP, Trapa PE, Maurer TS. Impact of Recovery on Fraction Unbound Using Equilibrium Dialysis. J Pharm Sci. 2012;101:1327–35.

Article  CAS  PubMed  Google Scholar 

Yamazaki H, Inoue K, Turvy CG, Guengerich FP, Shimada T. Effects of Freezing, Thawing, and Storage of Human Liver Samples on the Microsomal Contents and Activities of Cytochrome P450 Enzymes. Drug Metab Dispos. 1997;25:168–74.

CAS  PubMed  Google Scholar 

Riccardi K, Cawley S, Yates PD, Chang C, Funk C, Niosi M, et al. Plasma Protein Binding of Challenging Compounds. J Pharm Sci. 2015;104:2627–36.

Article  CAS  PubMed  Google Scholar 

Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC. Targeted Quantitative Proteomics for the Analysis of 14 UGT1As and -2Bs in Human Liver Using NanoUPLC–MS/MS with Selected Reaction Monitoring. J Proteome Res. 2013;12:4402–13.

Article  CAS  PubMed  Google Scholar 

Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, et al. Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors. Drug Metab Dispos. 2012;40:1051–65.

Article  CAS  PubMed  Google Scholar 

Pattanawongsa A, Nair PC, Rowland A, Miners JO. Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition. Drug Metab Dispos. 2016;44:378–88.

Article  CAS  PubMed  Google Scholar 

Miners JO, Rowland A, Novak JJ, Lapham K, Goosen TC. Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacol Ther. 2021;218:107689.

Article  CAS  PubMed  Google Scholar 

Lapham K, Lin J, Novak J, Orozco C, Niosi M, Di L, et al. 6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1. Relative to β-Estradiol Drug Metab Dispos. 2018;46:1836–46.

Article  CAS  PubMed  Google Scholar 

Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human udp-glucuronosyltransferases. Drug Metab Dispos. 2006;34:449–56.

Article  CAS  PubMed  Google Scholar 

Mendonza A, Hanna I, Meyers D, Koo P, Neelakantham S, Zhu B, et al. Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid. J Clin Pharmacol. 2016;56:355–64.

Article  CAS  PubMed  Google Scholar 

Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33:1729–39.

Article  CAS  PubMed  Google Scholar 

Kazmi F, Yerino P, Barbara JE, Parkinson A. Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor. Drug Metab Dispos. 2015;43:1294–302.

Article